Background: This study evaluated long-term outcomes in patients with pulmonary arterial hypertension (PAH) undergoing treatment with ambrisentan monotherapy, a selective oral endothelin-1 receptor antagonist. Methods and Results: Patients who participated in the Ambrisentan in Pulmonary Arterial Hypertension: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Efficacy Study (ARIES-1) clinical trial and extension phase at our institution were included. Cardiac catheterization, 6-minute walk distance (6MWD), and cardiac magnetic resonance (MRI) data were retrospectively reviewed. Twelve patients with PAH (11 idiopathic, 1 fenfluramine) had follow-up from 3 to 5.5 years from the initiation of ARIES-1. Patients received ambrisentan therapy throughout the study period and were on ambrisentan monotherapy for the first 2 years. At year 1, improvements in median mean pulmonary arterial pressure (PA), cardiac output, and pulmonary vascular resistance (PVR) were seen (P 5 .02, P 5 .03, P ! .01), and the improvement in PVR persisted at 2 years. 6MWD also improved significantly between baseline (350 m) and 1 and 2 years (397 m, P ! .01 and 393 m, P 5 .01). Cardiac MRI results were more varied, with an increase in RVejection fraction from 29% at baseline to 46% at 2 years (P 5 .02), but other MRI variables did not improve. Conclusions: Ambrisentan monotherapy led to improvements in catheterization, 6MWD, and RV ejection fraction, and shows promise as a long-term treatment for pulmonary arterial hypertension. (J Cardiac Fail 2010;16:121e127) 
Ambrisentan (Letairis; Gilead; Foster City, CA) is an oral endothelin-1 receptor antagonist (ERA) approved in 2007 for the treatment of World Health Organization functional class II and III pulmonary arterial hypertension (PAH).
Ambrisentan is the second endothelin-1 receptor antagonist to receive approval, and unlike the dual endothelin-1 receptor antagonist, bosentan (Tracleer; Actelion, Allschwil, Switzerland), ambrisentan is a selective antagonist for the endothelin A receptor. Endothelin-1 causes vasoconstriction and pulmonary artery smooth muscle cell growth mainly through its actions on the endothelin A receptor, whereas the endothelin B receptor is the predominate site for clearance of endothelin-1. 1 Ambrisentan has been shown to lead to improvement in functional class, walk distance, and time to clinical worsening relative to placebo in 2 Phase 3, placebo-controlled, 12-week clinical trials (total n 5 394) 2 and to lead to improved cardiopulmonary hemodynamics in an uncontrolled 12-week dose ranging study (n 5 64). 3 However, the long-term effects of ambrisentan on hemodynamics and right ventricular performance have not been reported. Additionally, there are few studies evaluating serial cardiac magnetic resonance imaging (MRI) results for patients treated with any of the approved PAH medications.
In this retrospective study, we evaluate cardiac catheterization and MRI data, and 6-minute walk distance (6MWD) in 12 patients treated with first-line ambrisentan therapy over 3.5 to 5 years. Patients were randomized 1:1:1 to placebo, ambrisentan 5 mg or 10 mg once daily for 12 weeks. Patients were then given the option to enter the extension phase (ARIES-E) where those on active drug continued on the same dose and those on placebo were randomized to 5 or 10 mg ambrisentan daily. Patients could also enter the extension phase through a protocol-specified escape route: patients receiving placebo during the initial phase of the study who then developed evidence of worsening PAH could be withdrawn from the study and then receive ambrisentan in the extension study. During the extension study, add-on therapy (other approved, non-ERA, PAH therapy) was allowed at the discretion of the treating physician; after ambrisentan received Food and Drug Administration approval, patients were transitioned to commercially available ambrisentan. Duration of follow-up for each patient was determined from the time of the enrollment in the ARIES-1 trial to the last available follow-up.
Follow-up testing included 6MWD testing every 3 months. In addition and separate from ARIES-1 study procedures, patients at our institution underwent right-sided heart catheterization and cardiac MRI on an approximately annual basis. The cardiac MRI imaging was performed on a GE 1.5 T scanner (GE Healthcare, Milwaukee, WI) using Fiesta cine short-axis images; left and right heart volume and mass measurements were performed using MASS software (MEDIS, Leiden, the Netherlands). Plasma brain natriuretic peptide (BNP) levels (pg/mL) were not routinely checked during the earlier years of the study. The most recent results are reported in the Patient Details when available.
Statistical Analysis
Changes in hemodynamics, 6MWD, and cardiac MRI results between baseline, 1, and 2 years were analyzed using Wilcoxon rank-sum test. Comparison of baseline values with normal values for cardiac MRI 4 was performed using a z conversion to account for the difference between the male and female normal ranges. SPSS 16.0 (SPSS Inc, Chicago, IL) was used for the statistical analysis, and P values !.05 were considered statistically significant. 6MWD, right-sided heart catheterization, and cardiac MRI data are reported for the 12 patients who entered the extension study and thus had serial evaluations available. All results are reported as medians. For the Kaplan-Meier curves of survival, all 14 of the originally enrolled patients were included. This study was approved by the University of Texas Southwestern Institutional Review Board.
Results
Fourteen patients at our institution (mean age 46 years, range 18 to 67 years) were enrolled in the ARIES-1 clinical trial. One patient died (described further in the following section) and 1 patient withdrew consent (both randomized to the placebo arm) during the initial 12-week randomized portion of the study. The remaining 12 patients entered the long-term, extension study ( Fig. 1) , where all received ambrisentan treatment. Eleven patients had idiopathic PAH, and 1 patient had prior fenfluramine exposure. No patients were diagnosed with familial PAH. At baseline of ARIES-1, all patients had severe PAH as evidenced by the hemodynamic data, World Health Organization classification, and exercise capacity (Tables 1 and 2) .
Results of the cardiac catheterization, cardiac MRI data, and 6MWD for these 12 patients were collected over 2 years, whereas survival and add-on therapy data were collected over 3.5 to 5 years; 1 patient had limited testing because of financial constraints. All patients remained on ambrisentan monotherapy for the initial 2 years. Afterwards, add-on therapy was required, as detailed in the following section. Add-on therapy (oral or intravenous) was not needed before the 2-year follow-up period; thus, the 2-year cardiac MRI, catheterization, and 6MWD data represent ambrisentan monotherapy.
Cardiac Catheterizations
Baseline catheterizations were performed within the 4 months before the initiation of the ARIES-1 trial. Baseline hemodynamic data were abnormal in all patients with a median pulmonary arterial pressure of 62 mm Hg (mean pressure) and pulmonary vascular resistance of 14.6 Wood units. Evidence of cardiac compromise was seen with the depressed median cardiac index of 2.0 L/min/m 2 . After 1 year of therapy, significant improvements in pulmonary arterial pressure, cardiac output, and pulmonary vascular resistance were seen (Table 2 ). This improvement was maintained in most patients at 2 years, although 2 patients showed a significant increase (O10%) in pulmonary artery pressures. Pulmonary vascular resistance at year 2 was similar to year 1, and remained significantly lower than baseline, and there was a trend in improvement of mean pulmonary artery wedge pressure (0.05) and cardiac output (0.09).
Exercise Capacity
Baseline 6MWD was performed between 1 and 6 days before the start of the ARIES-1 trial. Study patients showed impairment of exercise capacity with a median baseline distance of 350 m. At 1-year follow-up, the median 6MWD had improved to 397 m (P ! .01). At year 2, the 6MWD was unchanged at 393 m, but remained a significant improvement from baseline (P 5 .01) (Fig. 2) .
Cardiac MRI
Baseline cardiac MRI studies were performed prior to initiation of ambrisentan in 5 patients, within the first month of ambrisentan treatment in 3 patients, and during the first 4 months of therapy in 4 patients, dated from initiation of ambrisentan after adjustment for the placebo period (all dates in this article outside of this section include the placebo-controlled period). Unlike cardiac catheterization, which is required in all patients at our center before the initiation of a PAH-specific medication, a pretreatment cardiac MRI is preferred but not required. Thus some ''baseline'' cardiac MRI measurements were performed after the initiation of therapy. Study patients showed markedly abnormal ventricles compared with normals 4 (Table 2 , Fig. 3 ) on baseline MRI measurements. The median right ventricular (RV) end-diastolic volume indexed was elevated at 80 mL/m 2 and the median RV ejection fraction was depressed at 29% (normal 61%). 4 Follow-up MRI data was missing altogether for 1 patient and RV mass values were unavailable for a second patient. At 1-year follow-up, there was no significant change from baseline in right and left ventricular volumes and function. By 2 years, however, there was statistically significant improvement in RV ejection fraction compared with baseline (P 5 .02), but no significant change in the indexed RV mass or end-diastolic volume.
Survival and Requirement for Add-on PAH Therapy
Fourteen patients were initially randomized to placebo or ambrisentan under the ARIES-1 protocol. One patient randomized to placebo worsened unexpectedly during the second month of the study, and through the protocol-specific escape route was enrolled into the extension study and began ambrisentan treatment. She continued to decline rapidly due to what was subsequently diagnosed as a severe lupus flare and died a few weeks later. A second patient randomized to placebo withdrew from the trial, but continued to be followed in our clinic for several years. To date, she has not received ambrisentan.
All 12 patients who enrolled in the extension study after the 12-week randomization remained on ambrisentan monotherapy during the first 2 years of follow-up, and most remained stable during this initial 2-year period. However, 4 patients developed worsening symptoms requiring initiation of intravenous therapy: 2 toward the latter part of the second year (patients 4 and 5) and 2 in later clinical follow-up.
Add-on combination oral therapy has subsequently became more readily available and more widely used, and most (7 of 8) of the remaining patients received at least a trial of combination oral therapy during their third or fourth year of follow-up. Of the surviving patients, 5 remain on combinations of oral therapies: 3 are on ambrisentan monotherapy and 2 are on ambrisentan plus an intravenous prostacyclin (Fig. 4) .
Patient Details
Patient 1: Ambrisentan D Oral Treprostinil. Female, 40s, alive. Oral treprostinil was added during year 3. With combination therapy, symptoms remain stable and walk distance remains in the low 400 m, and the last BNP was 37 pg/mL. Patient 2: Ambrisentan D Attempt of Intravenous Epoprostenol. Female, 60s, deceased. Ambrisentan led to improvement in symptoms, and walk distance also improved to a peak distance of 413 m. However, after 3 years of treatment, walk distance fell precipitously to 69 m, and repeat catheterization and MRI showed marked worsening PAH (right atrial pressure 11 mm Hg, mean pulmonary artery pressure 65 mm Hg, cardiac index of 2.3 L/min/m 2 , RV ejection fraction of 36%). Epoprostenol was attempted, but she became profoundly hypoxic even on 15 L oxygen, and it was discontinued; she died 2 weeks later. She had known mild chronic obstructive pulmonary disease on study entry in 2004 (forced expiratory volume in 1 second 70% predicted); computed tomography angiogram at the time epoprostenol was attempted showed evidence of emphysematous changes, no new findings, no pulmonary emboli. The last BNP was 387 pg/mL, which had increased from 37 pg/mL approximately 8 months prior. Patient 3: Ambrisentan Monotherapy. Female, 60s, alive. After 4 years of ambrisentan, sildenafil was added for persistent exertional symptoms. However, she felt worse (short of breath, sinus congestion) and it was discontinued. She has stable, mildly abnormal hemodynamics (mean pulmonary artery pressure !30 mm Hg) and normal RV function. The BNP has always been less than 10 pg/mL. Patient 4: Ambrisentan D Intravenous Epoprostenol. Female, 40s, alive. After improvement between years 0 and year 1 on ambrisentan, symptoms and other tests worsened at 2 years, and intravenous epoprostenol was initiated. Pulmonary artery pressures remain in the mid-50s, Male, older teenager, alive. Ambrisentan led to considerable improvement in symptoms and hemodynamics, but the markedly dilated right ventricle improved only modestly and then began dilating again, RV function remained poor, and symptoms were (slightly) increasing. Intravenous treprostinil was begun with improvement in mean pulmonary artery pressure to the high 40s, and walk distance increased to 491 m (he is 6 0 tall), and a stable BNP in the 70s pg/mL. However, RV ejection fraction remains in the high teens and the right heart has continued to dilate. After 2 years of ambrisentan monotherapy, oral treprostinil was attempted but discontinued because of side effects and he was begun on sildenafil. Symptoms have improved and catheterization/MRI results have not worsened, but given the severity of the abnormalities, intravenous therapy was recommended; this was declined. The last BNP was 79 pg/mL, and he remains clinically stable. Patient 10: Ambrisentan D Intravenous Treprostinil. Female, 50s, deceased. Ambrisentan led to initial improvement in symptoms, walk distance, and hemodynamics, but because of persistent symptoms and catheterization abnormalities, oral treprostinil was begun during year 4. Several months later, she developed a sepsis syndrome with fever and hypotension leading to an intensive care unit admission. Antibiotics were begun, and intravenous epoprostenol as well as pressors were required to treat decompensated right heart failure. She recovered, and epoprostenol was changed to intravenous treprostinil because of patient preference. One year later she developed pneumonia along with progressive right heart failure, and she died several weeks later; multiple BNP levels were O1000 pg/mL. Patient 11: Ambrisentan D Oral Treprostinil. Female, 50s, alive. Oral treprostinil was added during year 3. The BNP level fell from 743 pg/mL pretreatment to most recently 108 pg/mL. Symptoms have remained stable, Table 2 . catheterization has modestly improved, and last walk distance was 475 m.
Patients 12: Ambrisentan D Sildenafil. Female, 20s, alive. During year 4, oral treprostinil was added because of stable but persistent symptoms, but it was subsequently discontinued because of significant side effects and sildenafil was begun. Despite combination therapy, catheterization results have worsened slightly; walk distance and BNP level at the visit was 349 m and 36 pg/mL, respectively.
Discussion
In this study, we describe significant improvements in cardiac catheterization hemodynamics, 6MWD, and cardiac MRI results for 12 PAH patients receiving open-label ambrisentan monotherapy for a period of 2 years. This study on its own is not large enough to make widely generalizable predictions on how other PAH patients will respond to treatment with ambrisentan, but it does add significantly to the existing literature. Prior studies have shown that ambrisentan, at current Food and Drug Administratione approved doses (5 to 10 mg), leads to 31 to 59 m improvements in 6MWD compared with placebo over 12 weeks, and that these improvements in walk distance are maintained at 48 weeks (ARIES-1 and -2). Additionally, ambrisentan has also been shown to lead to improvements in hemodynamics relative to baseline at 12 weeks (n 5 64 total, 29 received the now approved 5-or 10-mg dose). 3 This descriptive study is the first to suggest that both the 6MWD and hemodynamic improvements with ambrisentan treatment may be maintained at 1 to 2 years, and it is also the first study to report on cardiac MRI results in ambrisentan patients. Statistically significant improvements were seen in 6MWD, cardiac index, pulmonary arterial pressure, and pulmonary vascular resistance at 1 year, and improvements in exercise capacity and pulmonary vascular resistance remained significant at 2 years. Looking at individual patients, almost all patients showed at least some improvement between baseline and 1-year follow-up in most of these measures. Exercise capacity and hemodynamics are strong predictors of outcome in PAH, and the sustainability of these results is encouraging. Cardiac MRI results were mixed, with improvement in RV ejection fraction over 2 years but no statistical significant improvement in RV end-diastolic volume index or RV mass. This lack of improvement in RV end-diastolic volume index and mass index was seen despite a mean 10 mm Hg drop in mean pulmonary arterial pressures, a mean 1.1 L/min increase in cardiac output, and a mean 31% reduction in pulmonary vascular resistance by right heart catheterization. The lack of a true baseline for some patients may have lead to an underestimation of the effects, but RV function clearly remained very abnormal in many patients at both 1 and 2 years of therapy.
Failure to see improvement in RV size, despite hemodynamic improvement, has been seen in other studies of PAH, including studies of bosentan and epoprostenol, with assessment of RV size and function by either echocardiogram 12e15 This is in contrast to the marked improvement in RV size and RV ejection fraction seen after lung transplantation in PAH or successful pulmonary thromboendarterectomy in chronic thromboembolic pulmonary hypertension. It is likely, therefore, that the failure to improve is related to persistent hemodynamic abnormalities rather than irreversible cardiac injury. 16e18 Interestingly, most patients in our cohort did not have worsening RV end-diastolic volume index or RV ejection fraction. In a disease whose natural history is progressive decline in RV function, halting this decline may, in some cases, be considered at least a partial success.
Including the 2 patients who did not enter the long-term extension phase, survival in this group was 93% at 3 years follow-up, and 79% overall at 3.5e5 years follow-up (Fig. 4) . This compares favorably with reported survival rates with other PAH therapies. 11 Although the small sample size makes comparisons between actual and expected survival of limited utility, these results do at least suggest that a strategy of initial treatment with ambrisentan monotherapy could lead to very good overall survival rates, and larger studies should be conducted to assess this.
In addition to the small number of study patients, our data were limited by the lack of placebo controls for the long-term data, the retrospective data acquisition, and the failure to obtain all MRI studies before the initiation of therapy. Nevertheless, descriptive studies such as this may provide valuable information in areas that are unlikely to be addressed in experimental studies.
Conclusion
Mortality in pulmonary arterial hypertension has been shown to relate to RV failure. 19 Ambrisentan monotherapy at our institution led to improvements in both hemodynamics from cardiac catheterization as well as RV performance measured directly by cardiac MRI and indirectly by 6MWD. The results with the use of this oral, selective endothelin receptor antagonist show clinical promise for long-term therapy, although the modest improvements underline the need for continued therapeutic advances for pulmonary arterial hypertension.
